These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 11044791)

  • 1. Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.
    Ohta H; Masuda A; Fuyuki T; Sugimoto I; Suda Y; Makita K; Takamatsu K; Horiguchi F; Nozawa S
    Horm Res; 2000; 53(3):120-4. PubMed ID: 11044791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
    Ohta H; Komukai S; Sugimoto I; Fuyuki T; Makita K; Takamatsu K; Horiguchi F; Nozawa S
    Maturitas; 1998 Jun; 29(2):163-71. PubMed ID: 9651906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
    Tani S; Nagao K; Hirayama A
    Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of fluvastatin on hyperlipidemia after renal transplantation.
    Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
    Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetic study of statin therapy and cholesterol reduction.
    Chasman DI; Posada D; Subrahmanyan L; Cook NR; Stanton VP; Ridker PM
    JAMA; 2004 Jun; 291(23):2821-7. PubMed ID: 15199031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
    Iliadis EA; Rosenson RS
    Clin Cardiol; 1999 Jan; 22(1):25-8. PubMed ID: 9929751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
    Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
    Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy.
    Monson JP; Jönsson P; Koltowska-Häggström M; Kourides I
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):623-8. PubMed ID: 17581260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
    Grekas D; Kassimatis E; Makedou A; Bacharaki D; Bamichas G; Tourkantonis A
    Nephron; 2001 Aug; 88(4):329-33. PubMed ID: 11474227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
    Saito Y; Yamada N; Teramoto T; Itakura H; Hata Y; Nakaya N; Mabuchi H; Tushima M; Sasaki J; Goto Y; Ogawa N
    Arzneimittelforschung; 2002; 52(4):251-5. PubMed ID: 12040967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [HMG-CoA reductase inhibitor, pravastatin].
    Tsujita Y
    Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1919-28. PubMed ID: 8210434
    [No Abstract]   [Full Text] [Related]  

  • 16. Menopause and hyperlipidemia: pravastatin lowers lipid levels without decreasing endogenous estrogens.
    Honjo H; Tanaka K; Urabe M; Naitoh K; Ogino Y; Yamamoto T; Okada H
    Clin Ther; 1992; 14(5):699-707. PubMed ID: 1345259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels.
    Narita Y; Kitazoe Y; Kurihara Y; Okuhara Y; Takamatsu K; Saito N; Doi Y
    Eur J Clin Pharmacol; 1997; 52(6):461-3. PubMed ID: 9342581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated baseline triglyceride levels modulate effects of HMGCoA reductase inhibitors on plasma lipoproteins.
    Drmanac S; Heilbron DC; Pullinger CR; Jafari M; Gietzen D; Ukrainczyk T; Cho MH; Frost PH; Siradze K; Drmanac RT; Kane JP; Malloy MJ
    J Cardiovasc Pharmacol Ther; 2001 Jan; 6(1):47-56. PubMed ID: 11452336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ezetimibe reduces low-density lipoprotein cholesterol (LDL-C) in renal transplant patients resistant to HMG-CoA reductase inhibitors.
    Chuang P; Langone AJ
    Am J Ther; 2007; 14(5):438-41. PubMed ID: 17890931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.